NCT02268409View on ClinicalTrials.gov

Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 20, 2014

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions

β-Thalassemia

Interventions

DRUG

luspatercept

subcutaneous injection

Trial Locations (7)

Unknown

Acceleron Investigative Site, Athens

Acceleron Investigative Site, Brindisi

Acceleron Investigative Site, Catania

Acceleron Investigative Site, Ferrara

Acceleron Investigative Site, Modena

Acceleron Investigative Site, Naples

Acceleron Investigative Site, Turin

All Listed Sponsors

lead

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

INDUSTRY

NCT02268409 - Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004) | Biotech Hunter | Biotech Hunter